235 related articles for article (PubMed ID: 21490128)
1. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice.
van Waterschoot RA; Schinkel AH
Pharmacol Rev; 2011 Jun; 63(2):390-410. PubMed ID: 21490128
[TBL] [Abstract][Full Text] [Related]
2. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.
van Waterschoot RA; Lagas JS; Wagenaar E; van der Kruijssen CM; van Herwaarden AE; Song JY; Rooswinkel RW; van Tellingen O; Rosing H; Beijnen JH; Schinkel AH
Cancer Res; 2009 Dec; 69(23):8996-9002. PubMed ID: 19920203
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine.
Lagas JS; Damen CW; van Waterschoot RA; Iusuf D; Beijnen JH; Schinkel AH
Mol Pharmacol; 2012 Oct; 82(4):636-44. PubMed ID: 22767610
[TBL] [Abstract][Full Text] [Related]
4. Examination of CYP3A and P-glycoprotein-mediated drug-drug interactions using animal models.
Marathe PH; Rodrigues AD
Methods Mol Biol; 2010; 596():385-403. PubMed ID: 19949933
[TBL] [Abstract][Full Text] [Related]
5. Intestinal first-pass metabolism by cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption.
Dufek MB; Bridges AS; Thakker DR
Drug Metab Dispos; 2013 Sep; 41(9):1695-702. PubMed ID: 23821186
[TBL] [Abstract][Full Text] [Related]
6. The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.
Press RR; Buckle T; Beijnen JH; van Tellingen O
Cancer Chemother Pharmacol; 2006 Jun; 57(6):819-25. PubMed ID: 16163538
[TBL] [Abstract][Full Text] [Related]
7. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
Yasuda K; Lan LB; Sanglard D; Furuya K; Schuetz JD; Schuetz EG
J Pharmacol Exp Ther; 2002 Oct; 303(1):323-32. PubMed ID: 12235267
[TBL] [Abstract][Full Text] [Related]
8. The Consequence of Drug-Drug Interactions Influencing the Interplay between P-Glycoprotein and Cytochrome P450 3a: An Ex Vivo Study with Rat Precision-Cut Intestinal Slices.
Li M; de Graaf IA; Siissalo S; de Jager MH; van Dam A; Groothuis GM
Drug Metab Dispos; 2016 May; 44(5):683-91. PubMed ID: 26932816
[TBL] [Abstract][Full Text] [Related]
9. Importance of P-glycoprotein for drug-drug interactions.
Glaeser H
Handb Exp Pharmacol; 2011; (201):285-97. PubMed ID: 21103973
[TBL] [Abstract][Full Text] [Related]
10. P-Glycoprotein- and cytochrome P-450-mediated herbal drug interactions.
Kumar YS; Adukondalu D; Sathish D; Vishnu YV; Ramesh G; Latha AB; Reddy PC; Sarangapani M; Rao YM
Drug Metabol Drug Interact; 2010; 25(1-4):3-16. PubMed ID: 21417789
[TBL] [Abstract][Full Text] [Related]
11. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
12. Deconvoluting the effects of P-glycoprotein on intestinal CYP3A: a major challenge.
Knight B; Troutman M; Thakker DR
Curr Opin Pharmacol; 2006 Oct; 6(5):528-32. PubMed ID: 16899406
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism.
Dufek MB; Knight BM; Bridges AS; Thakker DR
Drug Metab Dispos; 2013 Mar; 41(3):642-50. PubMed ID: 23288866
[TBL] [Abstract][Full Text] [Related]
14. Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.
Ikemura K; Urano K; Matsuda H; Mizutani H; Iwamoto T; Okuda M
J Pharmacol Exp Ther; 2009 Jan; 328(1):249-55. PubMed ID: 18842703
[TBL] [Abstract][Full Text] [Related]
15. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 3A [correction of P-450 A] and p-glycoprotein induction .
Lin JH; Chiba M; Chen IW; Nishime JA; deLuna FA; Yamazaki M; Lin YJ
Drug Metab Dispos; 1999 Oct; 27(10):1187-93. PubMed ID: 10497146
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.
Hirunpanich V; Murakoso K; Sato H
Int J Pharm; 2008 Mar; 351(1-2):133-43. PubMed ID: 18082981
[TBL] [Abstract][Full Text] [Related]
17. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.
Ward KW; Stelman GJ; Morgan JA; Zeigler KS; Azzarano LM; Kehler JR; McSurdy-Freed JE; Proksch JW; Smith BR
Drug Metab Dispos; 2004 Feb; 32(2):172-7. PubMed ID: 14744938
[TBL] [Abstract][Full Text] [Related]
18. Effect of interferon-gamma on the pharmacokinetics of digoxin, a P-glycoprotein substrate, intravenously injected into the mouse.
Kawaguchi H; Matsui Y; Watanabe Y; Takakura Y
J Pharmacol Exp Ther; 2004 Jan; 308(1):91-6. PubMed ID: 14569074
[TBL] [Abstract][Full Text] [Related]
19. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats.
Zhang W; Tan TM; Lim LY
Drug Metab Dispos; 2007 Jan; 35(1):110-5. PubMed ID: 17050652
[TBL] [Abstract][Full Text] [Related]
20. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
